Correlation Between Loncar Cancer and SPDR SP

Can any of the company-specific risk be diversified away by investing in both Loncar Cancer and SPDR SP at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Loncar Cancer and SPDR SP into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Loncar Cancer Immunotherapy and SPDR SP Software, you can compare the effects of market volatilities on Loncar Cancer and SPDR SP and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Loncar Cancer with a short position of SPDR SP. Check out your portfolio center. Please also check ongoing floating volatility patterns of Loncar Cancer and SPDR SP.

Diversification Opportunities for Loncar Cancer and SPDR SP

-0.64

Correlation Coefficient

Loncar Cancer  SPDR SP

Excellent diversification

The 3 months correlation between Loncar and SPDR is -0.64. Overlapping area represents the amount of risk that can be diversified away by holding Loncar Cancer Immunotherapy and SPDR SP Software in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on SPDR SP Software and Loncar Cancer is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Loncar Cancer Immunotherapy are associated (or correlated) with SPDR SP. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of SPDR SP Software has no effect on the direction of Loncar Cancer i.e., Loncar Cancer and SPDR SP go up and down completely randomly.

Pair Corralation between Loncar Cancer and SPDR SP

Given the investment horizon of 90 days Loncar Cancer Immunotherapy is expected to under-perform the SPDR SP. In addition to that, Loncar Cancer is 1.54 times more volatile than SPDR SP Software. It trades about -0.04 of its total potential returns per unit of risk. SPDR SP Software is currently generating about 0.16 per unit of volatility. If you would invest  14,600  in SPDR SP Software on September 22, 2024 and sell it today you would earn a total of  4,859  from holding SPDR SP Software or generate 33.28% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Loncar Cancer Immunotherapy  vs.  SPDR SP Software

Loncar Cancer Immuno

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Loncar Cancer Immunotherapy has generated negative risk-adjusted returns adding no value to investors with long positions. Even with abnormal performance in the last few months, the Etf's fundamental indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the ETF retail investors.

SPDR SP Software

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in SPDR SP Software are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, SPDR SP showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Loncar Cancer and SPDR SP

The main advantage of trading using opposite Loncar Cancer and SPDR SP positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Loncar Cancer position performs unexpectedly, SPDR SP can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SPDR SP will offset losses from the drop in SPDR SP's long position.

The idea behind Loncar Cancer Immunotherapy and SPDR SP Software pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.